PeerVoice Oncology & Haematology Video

Teresa Tiano, Honours B.A. - A Challenging Journey: A Patient-Centred Perspective on Gastric Cancer

Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer

Ravi Ramjeesingh, MD, PhD, FRCPC - Immunotherapy for Biliary Tract Cancers: Changing the Narrative in Rare and Aggressive Tumours

Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy

Philippe Moreau, MD - Assessing Current and Potential Approaches in Multiple Myeloma: Updates From Madrid 2024

Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?

Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma

Shaji Kumar, MD - Age Is More Than Just a Number: Tailoring Treatment Across the Multiple Myeloma Journey for Our Older and/or Unfit Patients

María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance

David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey

Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC

Jeffrey Habert, MD, CCFP, FCFP - Steps Towards Earlier Detection of Lung Cancer: Harnessing the Power of Primary Care

Mohamed El-Hussein, RN, PhD, NP / Caitlin Carreau, MN, RN(EC) - At the Forefront of Cancer Prevention: Nursing Strategies to Optimize HPV Immunization

Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents

Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria

Abdulazeez Salawu, MBBS, MSc, PhD - The Case for Biomarker-Guided Management of mCRC: Steps to Refine Care Along the Patient’s Journey

Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer

Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?

Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC

Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes

Matthew Kang, MD, FRCPC - Putting the Individual in ITP: Enhancing Patients Outcomes With TPO-RAs

George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action

Geoffrey Liu, MD, MSc, FRCPC, FISPE - Optimizing the Potential for Patients With ALK-Positive mNSCLC Throughout Their Treatment Journey